Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous heart attack or stroke and followed them for a median of 4.6 years. The mortality reduction began to appear after approximately 1.5 years.
The finding adds to the trial’s primary results. Repatha reduced the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 25%, while lowering the risk of a broader cardiovascular composite by 19%. Repatha also reduced the risk of myocardial infarction by 36%. In a lipid substudy, median low-density lipoprotein cholesterol, or LDL-C, at 48 weeks reached 45 mg/dL with Repatha, compared with 109 mg/dL for placebo.
The central question is whether stronger outcomes evidence can move the PCSK9 inhibitor earlier in treatment, before a patient’s first major cardiovascular event.
Bull Case
A mortality benefit gives physicians, guideline committees, and payers a more consequential reason to consider earlier PCSK9 treatment. The protocol placed patients on their highest tolerated statin and/or ezetimibe regimen, although approximately 8% were not receiving lipid-lowering therapy at baseline. The results are therefore relevant to high-risk patients whose LDL-C remains uncontrolled despite available treatment.
The commercial foundation is already in place. According to Amgen Inc., Repatha has been studied for 15 years across 51 clinical trials involving more than 57,000 patients, and approximately 9 million patients have received the drug globally. The FDA broadened Repatha’s U.S. indication in 2025 to adults at increased risk of major cardiovascular events because of uncontrolled LDL-C. The European Commission expanded its indication in August 2026 based on VESALIUS-CV.
Amgen Inc. may not need an entirely new patient population to generate growth. Better mortality evidence could increase physician confidence and support broader reimbursement, although its effect on patient persistence remains unproven.
Bear Case
Mortality was a prespecified secondary analysis, not the trial’s primary endpoint. The reported 20% figure is a relative risk reduction, and Amgen Inc. did not provide absolute mortality event rates in the announcement. For context, the absolute reductions in the trial’s primary three-part and four-part cardiovascular endpoints were 1.8 and 2.8 percentage points, respectively, but those figures are not measures of the mortality benefit.
The enrolled patients were carefully selected. They had established atherosclerotic disease or high-risk diabetes, elevated LDL-C, and no prior heart attack or stroke. The findings support earlier use in a high-risk group, not broad use among everyone with elevated cholesterol.
Adoption still faces practical barriers. Repatha is injectable, while statins and ezetimibe are lower-cost oral treatments. Payer restrictions can slow access, and the U.S. label is already broad enough that the next leg of expansion may depend more on guidelines, reimbursement, and prescribing behavior than another regulatory change.
Hedge Fund Sentiment
The filings available so far reflect positions held before Amgen Inc. reported the VESALIUS-CV mortality analysis. Insider Monkey’s database showed 66 hedge funds holding Amgen Inc. at the end of 2Q2026, up from 65 funds three months earlier.
Conclusion
The VESALIUS-CV mortality analysis strengthens the case for using Repatha before a first heart attack or stroke. It also reinforces the value of sustained LDL-C lowering in patients who remain at high risk despite standard therapy. Still, the market opportunity will be determined by the absolute benefit, guideline adoption, payer access, and patient willingness to use an injectable drug. The evidence improves the earlier-use case for Amgen Inc., but reimbursement and implementation will determine how much that evidence expands the market.
READ NEXT: ConocoPhillips (COP): Wall Street Sees More Upside Despite Leadership Shakeup and Here is Why Chevron (CVX) is a Favorite Among Hedge Funds
This article is originally published at Insider Monkey.
Hedge Fund Resource Center